molecular-imaging
(3)
Alpha-9 Oncology
Alpha-9 Oncology is a clinical-stage radiopharmaceutical company engineering bespoke, tumor-targeting molecules that deliver alpha- and beta-emitting isotopes directly to cancer cells while sparing healthy tissue. Spun out of the University of British Columbia and BC Cancer in 2019 and now headquartered in Boston with research operations in Vancouver, the company iteratively optimizes each part of a radiopharmaceutical - binder, linker, chelator and radioisotope - to build a pipeline of paired imaging and therapy candidates. Backed by $258M in total funding, including a $175M Series C in 2024, Alpha-9 aims to expand precision radiotherapy across validated oncology targets.
Jack Hoppin
Jack Hoppin is the co-founder, chairman, and CEO of Ratio Therapeutics, a Boston-based biotech developing targeted radiopharmaceuticals for cancer. A mathematician by training with a PhD in applied mathematics, he previously co-founded the molecular imaging company Invicro and led Konica Minolta Precision Medicine. At Ratio he pairs with scientific co-founder John Babich to build fit-for-purpose radioligand therapies on the company's Trillium pharmacokinetic-modulation and Macropa chelation platforms, backed by investors including Bristol Myers Squibb and a partnership with Novartis.
Intravascular Imaging Incorporated (i3)
Intravascular Imaging Incorporated (i3) is a Wilton, Connecticut medical device company building a next-generation coronary imaging catheter. Its 3-French NIRF-IVUS catheter fuses intravascular ultrasound (IVUS), the clinical standard for guiding stent placement, with near-infrared fluorescence (NIRF) molecular imaging in a single device. The combination lets cardiologists see not just the anatomy of a coronary artery but the biology inside it - plaque inflammation, arterial dissections, transplant vasculopathy, and fibrin in unhealed stents. Spun out of work at Massachusetts General Hospital/Harvard Medical School and the Technical University of Munich, i3 aims to upgrade percutaneous coronary intervention (PCI) by helping doctors look beyond anatomy.